RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+14.7%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.47B
AUM Growth
+$335M
(+6.5%)
Cap. Flow
+$466M
Cap. Flow
% of AUM
8.53%
Top 10 Holdings %
Top 10 Hldgs %
51.96%
Holding
75
New
18
Increased
7
Reduced
14
Closed
5
Top Buys
| 1 |
Nkarta
NKTX
|
$168M |
| 2 |
Ascendis Pharma
ASND
|
$154M |
| 3 |
Seres Therapeutics
MCRB
|
$134M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
$109M |
| 5 |
VXRT
Vaxart
VXRT
|
$71.9M |
Top Sells
| 1 |
Novavax
NVAX
|
$386M |
| 2 |
TG Therapeutics
TGTX
|
$106M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$84.2M |
| 4 |
Stoke Therapeutics
STOK
|
$26.7M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$25.3M |
Sector Composition
| 1 | Healthcare | 93.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Keros Therapeutics
KROS
$632M
| $72.3M | 1.32% |
1,875,000
| – | – |
|
|
VXRT
27
DELISTED
Vaxart
VXRT
| $71.9M | 1.32% |
+10,810,937
| New | +$71.9M |
|
28
Wave Life Sciences
WVE
$1.3B
| $66M | 1.21% |
7,775,207
| – | – |
|
29
PMV Pharmaceuticals
PMVP
$76.3M
| $60.7M | 1.11% |
+1,710,265
| New | +$60.7M |
|
30
Dyne Therapeutics
DYN
$1.88B
| $56.6M | 1.04% |
+2,805,045
| New | +$56.6M |
|
|
INZY
31
DELISTED
Inozyme Pharma
INZY
| $52.7M | 0.96% |
+2,003,653
| New | +$52.7M |
|
32
Geron
GERN
$880M
| $52.4M | 0.96% |
30,126,299
| – | – |
|
|
AKUS
33
DELISTED
Akouos, Inc. Common Stock
AKUS
| $52.2M | 0.95% |
2,281,249
| – | – |
|
|
ORTX
34
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $50.6M | 0.93% |
1,231,521
+191,202
| +18% | +$7.86M |
|
35
Cardiff Oncology
CRDF
$142M
| $46.7M | 0.85% |
+3,290,000
| New | +$46.7M |
|
36
Relay Therapeutics
RLAY
$690M
| $42.6M | 0.78% |
+1,000,000
| New | +$42.6M |
|
|
INBX
37
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $38.3M | 0.7% |
+2,129,003
| New | +$38.3M |
|
38
Alector
ALEC
$285M
| $38.1M | 0.7% |
3,618,748
-508,600
| -12% | -$5.36M |
|
39
Crinetics Pharmaceuticals
CRNX
$3.23B
| $36.5M | 0.67% |
2,328,698
| – | – |
|
40
Arcutis Biotherapeutics
ARQT
$1.94B
| $34.1M | 0.62% |
1,165,184
| – | – |
|
41
Ardelyx
ARDX
$1.58B
| $32.9M | 0.6% |
6,260,904
| – | – |
|
|
VRNA
42
Verona Pharma
VRNA
$9.19B
| $31.8M | 0.58% |
+5,100,000
| New | +$31.8M |
|
43
Relmada Therapeutics
RLMD
$45.5M
| $29.4M | 0.54% |
781,290
-70,617
| -8% | -$2.66M |
|
44
scPharmaceuticals
SCPH
$300M
| $26.2M | 0.48% |
3,518,998
| – | – |
|
|
IMGN
45
DELISTED
Immunogen Inc
IMGN
| $25.3M | 0.46% |
+7,040,485
| New | +$25.3M |
|
46
Larimar Therapeutics
LRMR
$331M
| $23M | 0.42% |
1,515,151
| – | – |
|
47
Sutro Biopharma
STRO
$86.5M
| $21.3M | 0.39% |
2,118,212
+198,568
| +10% | +$2M |
|
48
Ocular Therapeutix
OCUL
$2.21B
| $20.8M | 0.38% |
2,727,272
| – | – |
|
|
PAND
49
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
| $20.3M | 0.37% |
+1,770,023
| New | +$20.3M |
|
|
PRVL
50
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $19.5M | 0.36% |
1,915,568
-579,123
| -23% | -$5.9M |
|